Oral Cancer Treatment in India
Get Oral Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Oral Cancer Treatment in UAE
Oral Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Oral cancer treatment encompasses a multidisciplinary spectrum of surgical resection, radiation therapy, and systemic chemotherapy or targeted biological agents, with curative intent achieved in over 80% of early-stage (Stage I–II) cases treated at high-volume oncology centres. India and the UAE have emerged as premier destinations for international patients seeking world-class oral oncology care at a fraction of Western costs, with centres holding JCI and NABH (India) or JCI and DHA (UAE) accreditations and managing thousands of head-and-neck oncology cases annually. GAF Healthcare connects patients to these institutions with end-to-end clinical coordination, ensuring seamless access to tumour boards, reconstructive surgeons, and post-treatment rehabilitation—making the journey as stress-free as the care is exceptional.
Hospital Stay: 7–21 days (varies by stage, resection complexity, and reconstruction requirements) • Total Stay in Country (Fit-to-Fly): 4–8 weeks (dependent on flap viability, swallowing rehabilitation, and wound healing clearance from the surgical team) • Success Rate: 80–90% five-year survival for Stage I–II; 40–60% for Stage III–IV with multimodal therapy
What Is It?
Oral cancer refers to malignant neoplasms arising within the oral cavity, encompassing the lips, buccal mucosa, hard palate, anterior two-thirds of the tongue (oral tongue), floor of the mouth, upper and lower alveolar ridges, and retromolar trigone. Squamous cell carcinoma (SCC) accounts for approximately 90% of all oral cavity malignancies, with the remainder comprising mucoepidermoid carcinoma, adenoid cystic carcinoma, verrucous carcinoma, and rare sarcomatous or melanocytic variants. The disease exerts profound physiological consequences: tumour infiltration of the intrinsic tongue musculature, mandible, or floor-of-mouth disrupts mastication, deglutition, and articulation, while perineural invasion along the inferior alveolar or lingual nerves produces neuropathic pain and sensory deficits. Lymphatic spread to ipsilateral or bilateral cervical nodal basins (levels I–IV) is a critical prognostic determinant, and distant metastasis to lungs, liver, or bone portends a significantly diminished survival horizon.
The physiological burden of oral cancer extends beyond the primary tumour. Patients frequently present with severe malnutrition secondary to odynophagia and trismus, necessitating enteral feeding via nasogastric tube or percutaneous endoscopic gastrostomy (PEG) before and after definitive treatment. Tumour-related immunosuppression, chronic tobacco and alcohol exposure (the dominant aetiological co-factors accounting for over 75% of cases in South and Southeast Asia), and HPV-16/18 co-infection further compound systemic vulnerability. Emerging evidence implicates areca nut (betel quid) chewing as an independent carcinogen, particularly relevant to the epidemiology of buccal mucosa carcinoma in South Asian populations.
The contemporary standard of care is driven by tumour site, clinical TNM staging (8th edition AJCC), depth of invasion (DOI) measurement on MRI or ultrasound, and molecular profiling. Early-stage disease is managed with primary surgical resection achieving histologically clear margins (≥5 mm) with or without elective neck dissection, and adjuvant radiotherapy is reserved for high-risk pathological features including positive margins, perineural invasion (PNI), lymphovascular space invasion (LVSI), or ≥2 positive cervical lymph nodes. Locally advanced disease mandates concurrent platinum-based chemoradiotherapy (cisplatin 100 mg/m² every 3 weeks) or, where surgical resection is feasible, composite resection with microvascular free-flap reconstruction followed by adjuvant (chemo)radiotherapy. The addition of anti-EGFR therapy (cetuximab) or immune checkpoint inhibitors (pembrolizumab, nivolumab) in the recurrent/metastatic setting has redefined systemic management in the post-EXTREME and KEYNOTE-048 era.
Candidates
• **Confirmed histopathological diagnosis**: Tissue biopsy (incisional or punch) with histological subtyping and grade is mandatory before any treatment planning.
• **Clinical staging workup**: Contrast-enhanced MRI of the primary site and neck (to assess depth of invasion, cortical bone involvement, and nodal characteristics), contrast-enhanced CT of chest/abdomen/pelvis or integrated PET-CT (18F-FDG) for distant metastasis staging, and orthopantomogram (OPG) or cone-beam CT when mandibular involvement is suspected.
• **Stage I–IVB oral cavity SCC**: Suitable for curative-intent treatment. Patients with resectable Stage I–II disease are optimal surgical candidates. Stage III–IVA patients may be candidates for composite resection with free-flap reconstruction or concurrent chemoradiation depending on surgical morbidity assessment.
• **Performance status**: ECOG Performance Status 0–2 preferred for aggressive multimodal therapy; ECOG 3 patients may be considered for palliative-intent radiation or single-agent systemic therapy.
• **Organ function thresholds**: Creatinine clearance ≥50 mL/min (for cisplatin eligibility), haemoglobin ≥10 g/dL, platelet count ≥100,000/µL, adequate hepatic function (AST/ALT <2.5× ULN).
• **Cardiovascular assessment**: 12-lead ECG, 2D echocardiography, and cardiology clearance required if prior anthracycline exposure or significant cardiac history. Baseline pulmonary function tests (spirometry) for patients planned for extensive neck dissection or thoracic procedures.
• **Dental evaluation**: Mandatory pre-radiation dental assessment and extractions of non-restorable teeth to reduce the risk of osteoradionecrosis (ORN) of the mandible.
• **Nutritional and speech-language assessment**: Baseline swallowing evaluation (FEES or modified barium swallow) and dietetic assessment to plan enteral nutrition support.
• **Contraindications (relative or absolute)**:
- Unresectable Stage IVB disease with carotid encasement (relative; consider definitive CRT)
- Stage IVC (distant metastatic) disease: curative intent contraindicated; systemic therapy or best supportive care
- Severe uncontrolled comorbidities (decompensated heart failure, NYHA Class IV; Child-Pugh C cirrhosis)
- Prior radiotherapy to the same field exceeding tolerance doses (re-irradiation is a specialist decision, not routine)
- Known hypersensitivity to platinum compounds (alternative regimens must be substituted)
- Active uncontrolled infection or bleeding diathesis precluding surgery
Procedure
**1. Surgical Resection — The Primary Curative Modality**
Surgical management is stratified by tumour site, size (T classification), depth of invasion (DOI), and mandibular proximity. Resection aims for a minimum 5 mm clear margin in all three dimensions.
• **Transoral Resection (TOR)**: Standard approach for accessible oral tongue, floor-of-mouth, and buccal lesions. Performed under general anaesthesia using cold-steel or electrosurgical techniques. Intraoperative frozen-section margin analysis is employed at high-volume centres.
• **Transoral Robotic Surgery (TORS)**: Although primarily established for oropharyngeal carcinoma, TORS (da Vinci Xi/SP platform) is increasingly applied to posterior oral tongue and retromolar trigone lesions, offering enhanced 3D visualisation, wristed instrument dexterity, and reduced thermal spread compared to conventional transoral laser microsurgery (TLM).
• **Mandibulotomy / Visor Flap Access**: Employed for posteriorly located tumours requiring wide access; involves a midline or paramedian mandibular osteotomy with subsequent rigid plate fixation.
• **Marginal Mandibulectomy**: Resection of the alveolar rim while preserving mandibular continuity; appropriate when tumour abuts but does not radiologically invade the cortical bone.
• **Segmental Mandibulectomy**: En bloc resection of a mandibular segment including tumour; mandates immediate vascularised bony reconstruction.
• **Maxillectomy (Infrastructure / Total)**: For hard palate and upper alveolar primaries; infrastructure maxillectomy preserves the orbital floor, while total maxillectomy includes the orbital floor when involved.
**2. Cervical Lymph Node Management**
• **Selective Neck Dissection (SND)**: Levels I–III (supraomohyoid) for clinically N0 oral cavity primary with DOI ≥4 mm (per ASCO/NCCN guidelines); elective dissection reduces occult nodal failure rates by approximately 24%.
• **Modified Radical Neck Dissection (MRND)**: For clinically or radiologically node-positive (cN+) neck; preserves sternocleidomastoid, internal jugular vein, and spinal accessory nerve unless directly invaded.
• **Sentinel Lymph Node Biopsy (SLNB)**: An emerging option for cT1–T2N0 disease at centres with nuclear medicine expertise (SENTINEL I/II trial data); reduces unnecessary elective dissection in node-negative patients.
**3. Microvascular Free-Flap Reconstruction**
Immediate reconstruction of surgical defects is the standard of care at accredited centres, preserving speech and swallowing function and maintaining facial contour.
• **Radial Forearm Free Flap (RFFF)**: The workhorse soft-tissue flap for oral tongue, floor-of-mouth, and buccal defects; thin, pliable, and reliable pedicle (radial artery/venae comitantes).
• **Anterolateral Thigh Free Flap (ALT)**: Preferred for larger soft-tissue defects; can be harvested with vastus lateralis muscle for obliteration of dead space.
• **Fibula Free Flap (FFF)**: Gold standard for composite mandibular reconstruction; provides up to 22–25 cm of vascularised cortical bone with reliable peroneal artery pedicle; compatible with subsequent osseointegrated dental implant placement.
• **Deep Circumflex Iliac Artery (DCIA) Flap**: Alternative osteocutaneous flap for mandibular reconstruction with superior bone height.
• **Pectoralis Major Pedicled Flap (PMPF)**: A regional myocutaneous flap used in salvage settings or when microsurgical expertise is unavailable; associated with higher complication and bulkiness rates.
**4. Radiation Therapy**
• **Intensity-Modulated Radiation Therapy (IMRT)**: Standard-of-care external beam technique; delivers 60–66 Gy to the primary tumour bed in 30–33 fractions with simultaneous integrated boost (SIB) while sparing parotid glands (mean dose <26 Gy), mandible, spinal cord, and brainstem. Superior xerostomia and dysphagia outcomes versus 3D-CRT.
• **Volumetric Modulated Arc Therapy (VMAT)**: A rotational IMRT delivery that reduces total treatment time per session.
• **Image-Guided Radiation Therapy (IGRT)**: Daily cone-beam CT (CBCT) verification minimises setup error and protects organs at risk.
• **Proton Beam Therapy (PBT)**: Available at select Indian and UAE centres; the Bragg peak physics reduces exit dose and is particularly advantageous in paediatric or reirradiation scenarios.
• **Brachytherapy**: Interstitial brachytherapy (iridium-192 HDR) remains a valid option for select oral tongue T1–T2 lesions at specialised centres, offering high local dose with minimal mucosal morbidity.
**5. Systemic Therapy**
• **Concurrent Cisplatin-Based Chemoradiation**: Standard for locally advanced or high-risk adjuvant settings; cisplatin 100 mg/m² on days 1, 22, 43 of radiation (or weekly 40 mg/m² protocol for renal/toxicity concerns).
• **Cetuximab (Anti-EGFR)**: An alternative to cisplatin-based concurrent regimens for patients with cisplatin-ineligibility (significant renal impairment, peripheral neuropathy, hearing loss); activates antibody-dependent cellular cytotoxicity (ADCC) via EGFR blockade.
• **Immune Checkpoint Inhibitors**: Pembrolizumab (anti-PD-1) is FDA/EMA-approved as first-line monotherapy for PD-L1 CPS ≥1 recurrent/metastatic HNSCC and in combination with platinum/5-FU (KEYNOTE-048). Nivolumab is approved as second-line therapy post-platinum failure (CheckMate 141).
• **Targeted Therapy — EGFR Pathway**: Afatinib and erlotinib are investigational in EGFR-amplified or HER2-positive oral SCC; biomarker-driven enrolment in clinical trials is encouraged.
• **Induction Chemotherapy (Docetaxel + Cisplatin + 5-FU / TPF)**: Considered in select bulky N3 disease to reduce nodal burden prior to definitive CRT; not standard of care outside clinical trial protocols.
**6. Emerging & Precision Oncology Approaches**
• **Next-Generation Sequencing (NGS) / Molecular Tumour Board**: Comprehensive genomic profiling (e.g., FoundationOne CDx) to identify CDKN2A deletions, PIK3CA mutations, PTEN loss, or TMB-high status guiding targeted or immunotherapy enrolment.
• **Photodynamic Therapy (PDT)**: A sphincter-sparing minimally invasive option for superficial oral premalignant lesions (severe dysplasia, carcinoma in situ) using topical or systemic photosensitisers (5-aminolevulinic acid, temoporfin) activated by 630 nm laser.
• **Carbon Ion Radiotherapy**: Investigational for recurrent or previously irradiated cases at a small number of globally accredited facilities.
Cost of Oral Cancer Treatment: India vs. UAE
The cost of oral cancer treatment varies considerably by disease stage, surgical complexity (whether reconstruction with a microvascular free flap is required), and the extent of adjuvant radiation or systemic therapy. India offers exceptional clinical outcomes at costs that are typically 50–70% lower than equivalent care in Western Europe, North America, or Australia. The UAE provides a premium oncology environment with cutting-edge technology, multilingual teams, and world-class hospitality, at a cost approximately 40–60% above India but still substantially below the United States or United Kingdom benchmarks. The figures below represent all-inclusive package ranges — surgical fees, anaesthesia, ICU and ward stay, pathology, basic medications, and radiation therapy where applicable — for the full curative treatment course.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $5,000 – $18,000 | ~56% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $12,000 – $40,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
**Phase 1: Pre-Arrival & Remote Consultation (Weeks 1–2)**
• Patient submits medical records, biopsy pathology report, imaging (MRI/CT/PET-CT), and blood investigations to GAF Healthcare's clinical coordination team.
• GAF Healthcare's oncology panel—comprising head-and-neck surgical oncologists, radiation oncologists, and medical oncologists—conducts a multidisciplinary tumour board (MDT) review and issues a detailed treatment plan with itemised cost estimate within 48–72 hours.
• Visa facilitation initiated: e-Medical Visa (India) or visa-on-arrival/prior arrangement (UAE) processed concurrently.
• Pre-travel optimisation: nutritional supplementation commenced, dental extractions (if indicated pre-radiation) coordinated locally, and PEG tube insertion scheduled at the destination centre if DOI and swallowing compromise suggest post-operative feeding requirement.
**Phase 2: Arrival & Pre-Treatment Assessment (Days 1–5)**
• GAF Healthcare's ground team meets patient and attendant at the airport; private transfer to accredited hospital or partner accommodation.
• Comprehensive oncology workup repeated or updated at destination: restaging MRI with diffusion-weighted imaging (DWI), PET-CT (if not performed within 6 weeks), ultrasound-guided fine-needle aspiration cytology (FNAC) of equivocal cervical nodes, pulmonary function tests, echocardiography, and full haematological/biochemical panel.
• Anaesthesia pre-assessment (including difficult airway evaluation by the head-and-neck anaesthesia team given potential trismus or supraglottic mass effect).
• Dental assessment and prophylactic extraction of compromised teeth.
• Speech-language pathology and physiotherapy baseline assessment.
• Nutritional optimisation: nasogastric feeding or parenteral nutrition initiated if oral intake is severely compromised.
• Signed informed consent and surgical/oncology team introduction.
**Phase 3: Surgical Intervention (Day 5–7)**
• Procedure performed under general anaesthesia with fibreoptic-assisted or video laryngoscope-guided intubation (nasotracheal route preferred for unobstructed surgical access).
• Primary resection (transoral, mandibulotomy, or composite resection depending on T stage and site) with intraoperative frozen-section margin control.
• Simultaneous or staged neck dissection (selective or modified radical) as indicated.
• Microvascular free-flap harvest and anastomosis (typically 4–10 hours of total operative time for complex composite resections with reconstruction).
• Tracheostomy performed electively if extensive floor-of-mouth or bilateral neck dissection anticipates post-operative airway oedema.
• Rigid fixation of mandibular reconstruction plate and flap inset by the reconstructive team.
**Phase 4: Immediate Post-Operative Care (Days 7–14)**
• Intensive Care Unit (ICU) monitoring for 24–72 hours: hourly free-flap clinical assessment (Doppler probe monitoring of perforators, skin paddle colour, turgor, and capillary refill).
• Antibiotic prophylaxis (broad-spectrum covering oral flora: amoxicillin-clavulanate or clindamycin in penicillin-allergic patients), thromboprophylaxis (LMWH), and proton pump inhibitor cover.
• Nasogastric or PEG feeding commenced on post-operative day 1 to maintain caloric targets (25–30 kcal/kg/day).
• Tracheostomy decannulation (if applicable) typically between days 5–10 once pharyngeal oedema resolves and cuff-deflation trials are tolerated.
• Speech and language therapy (SLT) initiated in ICU/ward: swallowing exercises, lip and tongue range-of-motion drills, voice conservation strategies.
• Physiotherapy: early mobilisation, shoulder rehabilitation post-neck dissection (addressing spinal accessory nerve neuropraxia).
• Wound and flap donor-site care.
**Phase 5: Adjuvant Treatment Planning & Commencement (Weeks 3–6)**
• Final histopathology review at the MDT: margin status, DOI, PNI, LVSI, extranodal extension (ENE), and pathological node count determine adjuvant treatment intensity.
• **No adjuvant treatment required**: T1–T2N0 with clear margins, no high-risk features — patient monitored with surveillance schedule.
• **Adjuvant radiotherapy alone (60 Gy / 30 fractions)**: Intermediate-risk features (close margins, single positive node without ENE).
• **Adjuvant concurrent chemoradiation (66 Gy + cisplatin)**: High-risk features (positive margins, ENE, ≥2 positive nodes, PNI, LVSI) — commences 4–6 weeks post-surgery, once wound healing is confirmed.
• Radiation planning: CT simulation with thermoplastic mask immobilisation, IMRT/VMAT plan optimisation, and CBCT-IGRT daily verification.
• IMRT typically delivered over 6–6.5 weeks (30–33 daily fractions, Monday–Friday).
**Phase 6: Recovery Milestones & Fit-to-Fly Assessment (Weeks 6–10)**
• **Week 4–5 post-surgery**: Oral diet trial (soft, pureed) commenced if swallowing assessment confirms safe pharyngeal clearance; PEG/NG tube weaning initiated.
• **Week 6**: End-of-treatment imaging (contrast MRI neck and chest CT) and clinical assessment for response or residual disease.
• **Week 6–8**: GAF Healthcare's clinical team coordinates fit-to-fly assessment with the surgical and radiation oncology teams. Clearance criteria include: wound healing complete, no active infection, haemodynamic stability, swallowing sufficient to maintain hydration orally or via portable PEG, and post-radiation mucositis resolving to Grade ≤1.
• **Week 8–10**: Majority of patients cleared for international travel. Long-haul flight considerations include deep vein thrombosis (DVT) prophylaxis (compression stockings, LMWH for high-risk patients), oral/airway moisturisation (saline spray for xerostomia), and PEG tube travel documentation if still in situ.
• **Follow-up plan**: Detailed surveillance protocol issued by GAF Healthcare — clinical examination and endoscopy every 6–8 weeks for year 1, imaging at 3 and 12 months, and annual thyroid function testing post-neck irradiation.
Risks & Considerations
Oral cancer treatment carries a defined and procedure-specific risk profile that every patient must understand before proceeding. Surgical risks include primary haemorrhage (intraoperative blood loss necessitating transfusion in 10–20% of major resections), free-flap failure (total or partial flap necrosis in 3–8% of cases at experienced centres, rising to 15% at lower-volume institutions), wound dehiscence or orocutaneous fistula (particularly in previously irradiated or malnourished patients), trismus progression, and permanent hypoglossal or marginal mandibular nerve injury leading to tongue deviation or lip weakness. Neck dissection carries a specific risk of chyle leak (1–3% of cases involving level IV dissection) and shoulder syndrome (trapezius atrophy and pain secondary to spinal accessory nerve neuropraxia, occurring in up to 30% of modified radical dissections). Radiation-related morbidity includes acute Grade 3–4 mucositis (severe mouth sores requiring opioid analgesia and enteral nutrition, occurring in 40–60% of patients receiving concurrent chemoradiation), xerostomia (dry mouth) persisting in 20–40% of patients long-term despite parotid-sparing IMRT, dysphagia requiring long-term PEG tube dependence (5–15%), osteoradionecrosis (ORN) of the mandible (2–8%, risk elevated with high bone doses, dental disease, and tobacco use), hypothyroidism (30–50% requiring lifelong levothyroxine supplementation post-neck irradiation), and radiation carotid arteriopathy increasing cerebrovascular risk years after treatment. Cisplatin-based chemotherapy risks include acute nephrotoxicity (mitigated by aggressive pre- and post-hydration protocols), sensorineural hearing loss (cumulative dose-dependent ototoxicity), peripheral sensorimotor neuropathy, significant nausea and myelosuppression. Patients on immune checkpoint inhibitors face immune-related adverse events (irAEs) including pneumonitis, colitis, hepatitis, and endocrinopathies, requiring prompt immunosuppressive management. All patients treated at GAF Healthcare partner institutions benefit from onsite clinical pharmacists, toxicity monitoring protocols, and 24-hour emergency oncology nursing support to detect and manage these complications promptly.
Top Hospitals for Oral Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Oral Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Vinod Raina
MBBS, MD (Internal Medicine), DM (Medical Oncology), Fellowship, Fellowship
Medical Oncologist
Fortis Memorial Research Institute, Gurgaon, India
40+ Yearsof experience
Dr. Vinod Raina is a distinguished figure in the field of Medical Oncology in India, with over 40 years of exemplary experience. He is currently associated with Fortis Memorial Research Institute in Gurugram, where he functions as the Chairman and Head of Medical Oncology and Hematology. His primary expertise lies in chemotherapy treatment and he was the first to perform high-dose chemotherapy in India. He also performed the first peripheral blood BMT in… Read more
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Frequently Asked Questions — Oral Cancer Treatment
The total cost of oral cancer treatment in India typically ranges from USD 5,000 to USD 18,000 for a complete curative course, which may include surgical resection (with or without microvascular free-flap reconstruction), cervical neck dissection, adjuvant intensity-modulated radiation therapy (IMRT), and standard chemotherapy where indicated. This represents a saving of 50–70% compared to equivalent treatment costs in the United States or United Kingdom. In the UAE (Dubai or Abu Dhabi), the same complete treatment course is estimated at USD 12,000 to USD 40,000, reflecting the premium infrastructure, higher operational costs, and luxury patient experience of JCI-accredited UAE oncology centres. Both destinations significantly undercut Western pricing while maintaining equivalent or superior clinical outcomes for head-and-neck oncology. The exact cost for an individual patient depends critically on the tumour stage, resection complexity, reconstruction type (e.g., fibula free flap vs. soft-tissue radial forearm flap), number of radiation fractions, and whether systemic therapy with agents such as cisplatin, cetuximab, or immunotherapy (pembrolizumab) is required. GAF Healthcare provides a fully itemised cost estimate after review of the patient's medical records by our tumour board, with no hidden fees.
The minimum recommended in-country stay before international air travel depends on the complexity of treatment received. For patients undergoing surgical resection alone (without free-flap reconstruction or adjuvant radiotherapy), fit-to-fly clearance is typically granted at 4–6 weeks post-operatively, once wound healing is confirmed, the tracheostomy (if placed) is decannulated, and swallowing function is sufficient to maintain safe hydration. For patients receiving microvascular free-flap reconstruction — the standard for most Stage II–IV resections — the surgical team requires a minimum of 6 weeks to confirm flap viability, donor-site healing, and adequate nutritional intake before flight clearance. Patients completing a full concurrent chemoradiation course (typically 6–6.5 weeks of daily IMRT) are cleared to fly approximately 2–4 weeks after the end of radiation, once acute mucositis has resolved to Grade 1 or below, haemoglobin is stable, and swallowing function allows adequate oral or PEG-tube-supported hydration for the flight duration. In practice, the total in-country stay for patients requiring surgery plus adjuvant chemoradiotherapy ranges from 10–14 weeks. GAF Healthcare's clinical coordinators manage the formal fit-to-fly assessment with the treating surgical and radiation oncology teams, and provide the patient with a medical summary letter and medication kit for the journey home. All international travellers are prescribed DVT prophylaxis (compression stockings and LMWH where indicated) for long-haul flights.
Success rates for oral cancer treatment are strongly stage-dependent and are best expressed as five-year overall survival (OS) and disease-free survival (DFS) rates. At JCI- and NABH-accredited high-volume head-and-neck oncology centres in India, and JCI- and DHA-accredited centres in the UAE, outcomes are benchmarked against or exceed international data from the SEER database and European ENCR registries. For Stage I oral cavity SCC (T1N0M0), five-year OS exceeds 85–90% with primary surgical resection and clear margins. Stage II disease (T2N0M0) achieves 70–80% five-year OS. Stage III (T3 or N1) disease managed with composite resection and adjuvant IMRT yields 50–65% five-year OS. Stage IVA–B disease treated with curative-intent surgery plus concurrent cisplatin chemoradiation achieves approximately 35–55% five-year OS at high-volume institutions, significantly better than community-level outcomes due to expertise in microvascular reconstruction, IMRT precision, and MDT-driven management. Patients with HPV-positive oropharyngeal disease (a distinct biological subset) have substantially better prognoses (five-year OS >80% for Stage I–II). It is important to note that 'success rate' in oncology encompasses not only survival but also functional outcomes: the rate of successful free-flap reconstruction with maintained speech and swallowing function exceeds 94% at GAF Healthcare's top-tier partner centres. Recurrence rates are further mitigated by strict surveillance protocols — clinical endoscopy every 6–8 weeks in year one, MRI at 3 and 12 months, and annual thyroid function testing post-irradiation — coordinated by GAF Healthcare's telemedicine follow-up programme.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully integrated, non-medical support infrastructure that begins from the moment a patient decides to travel and continues through discharge and beyond.
**Visa Assistance — India**: GAF Healthcare's documentation team guides patients through the Indian e-Medical Visa application (available to nationals of 156 countries), which permits a stay of up to 60 days with two extensions (total up to 180 days), sufficient for full surgical and adjuvant radiation courses. A Medical Attendant Visa (e-MED-X) is simultaneously processed for one accompanying family member at no additional charge. GAF Healthcare provides the official hospital invitation letter required for the visa application.
**Visa Assistance — UAE**: Most international patients enjoy visa-on-arrival, visa-free access, or straightforward tourist/medical visa access to Dubai and Abu Dhabi. GAF Healthcare coordinates with UAE partner hospitals to issue medical treatment letters supporting any patient requiring a formal medical visa. Long-stay patients are guided through visa extension procedures within the UAE.
**Airport Transfers & Ground Logistics**: Private, air-conditioned vehicle transfers are arranged between the international airport and hospital or accommodation for the patient and attendant on arrival and departure. All vehicles are adapted for patients with mobility limitations or those travelling with nasogastric or PEG tubes and portable equipment.
**Dedicated Medical Interpreter / Cultural Liaison**: A GAF Healthcare case manager — fluent in the patient's language (available for Arabic, Russian, French, Bengali, Pashto, Swahili, and other languages) — accompanies the patient throughout inpatient admissions, outpatient clinic visits, radiation sessions, and chemotherapy appointments, ensuring informed consent and clinical communication are never compromised by language barriers.
**Attendant Accommodation**: GAF Healthcare arranges comfortable, vetted accommodation (hospital guest house, serviced apartment, or partner hotel within walking distance or shuttle access from the hospital) for the patient's accompanying family member throughout the treatment stay. Meal arrangements and local orientation are included.
**Telemedicine Follow-Up**: Following discharge, GAF Healthcare facilitates scheduled video consultations between the patient's home-country physician and the treating oncology team at the destination centre, ensuring continuity of surveillance imaging review, toxicity management, and escalation pathways for recurrence.
**Emergency Repatriation Support**: In the rare event of a serious post-discharge complication, GAF Healthcare activates a medically supervised repatriation protocol in coordination with the treating centre and the patient's travel insurance provider.
Patients Also Explore
Other treatments commonly sought by patients considering Oral Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology